{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'All other lesions (or sites of disease) should be identified as non-target lesions and should also', 'be recorded at baseline. Measurements of these lesions are not required, but the presence or', 'absence of each should be noted throughout follow-up.', 'Radiographic response will be defined as a complete response (CR) or partial response (PR).', 'The following response criteria, modified from RECSIT 1.1, will be used:', 'Complete Response (CR):', 'Disappearance of all target lesions', 'At least a 30% decrease in the sum of the LD of target lesions,', 'Partial Response (PR):', 'taking as reference the baseline sum LD', 'At least a 20% increase in the sum LD of target lesions', 'Progressive Disease (PD):', '(including new measurable lesions), compared to the nadir sum', 'LD', 'Neither sufficient shrinkage to qualify for PR nor sufficient', 'Stable Disease (SD):', 'increase to qualify for PD, taking as reference the nadir sum LD', 'since the treatment started', 'Survival Endpoints:', 'Progression free survival (PFS) will be defined as the time from the start of treatment', 'until disease progression (per modified RECIST criteria or PCWG3 criteria for bone', 'lesions), clinical progression (as determined by the treating physician), or death,', 'whichever occurs first.', 'PSA PFS will be defined as the time from the start of treatment until PSA progression', '(as defined by PCWG3 criteria) [95].', 'Overall survival (OS) will be defined as the time from the start of treatment until death', 'from any cause.', 'It is important to note that bone metastases are considered non-measurable lesions.', 'Determining progression in bone metastases will therefore be defined according to PCWG3', 'criteria as follows:', 'Appearance of at least two new lesions on bone scan, with at least two additional', 'lesions on confirmatory bone scan. Confirmatory bone scan should ideally occur at', 'the next planned scan according to the Schedule of Study Assessments, but no earlier', 'than 4 weeks.', 'If at least two additional new lesions are seen on the confirmatory scan, the date of', 'progression is the date of the bone scan when the first two new lesions were', 'documented', '73(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Changes in intensity of uptake alone do not constitute either progression or', 'regression', '11.2', 'Calculation or derivation of safety variable(s)', '11.2.1', 'Other significant adverse events (OAE)', 'During the evaluation of the AE data, an AstraZeneca medically qualified expert will review', \"the list of AEs that were not reported as SAEs and DAEs. Based on the expert's judgment,\", 'significant adverse events of particular clinical importance may, after consultation with the', 'Global Patient Safety Physician, be considered OAEs and reported as such. A similar review', 'of laboratory, vital signs, ECG and other clinical data will be performed for identification of', 'OAEs.', 'Examples of these are marked hematological and other laboratory abnormalities, and certain', 'events that lead to intervention (other than those already classified as serious), dose reduction', 'or significant additional treatment.', 'There are currently no identified OAEs for olaparib', '11.3', 'Calculation or derivation of patient reported outcome variables', 'Quality of life (QOL) will be recorded through the FACT-P and the International Index of', 'Erectile Function (IIEF) surveys. These instruments has been previously validated and are', 'used extensively in clinical trials to assess the effects of treatment intervention on quality of', 'life. Details regarding these surveys can be found in Appendix 4.', '12.', 'STATISTICAL METHODS AND SAMPLE SIZE', 'DETERMINATION', '12.1', 'Description of analysis sets', 'The safety and efficacy analysis sets will include all subjects that received at least one dose of', 'the study drug. Subjects that drop out, for any reason, prior to 12-weeks (i.e. primary endpoint', 'assessment timepoint) will be replaced.', '12.2', 'Methods of statistical analyses', '12.2.1', 'Safety Analyses', 'We will characterize AEs by type and grade as outlined in Section 6.2. Safety will be', 'summarized as the severity and frequency of a given AE.', '74(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}